EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease

Recruiting Phase 1 Phase 2 Interventional Study
Intervertebral Disc Degeneration
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
20 and older
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
12 (estimated)
Sponsor
ASTEROGENE Biomedical Co. Ltd. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is an open-label, single-center Phase I/II clinical trial investigating the safety and efficacy of autologous nucleus pulposus cells (aNPC) in patients with disc degeneration. Eligible participants are those assessed by the principal investigator to have disc herniation suitable for discectomy and confirmed disc degeneration. During the treatment period, participants will receive a single inj…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Main inclusion criteria: 1. Age≧20 years old. 2. Diagnosed with a disc herniation, can be having a discectomy. 3. Having low back pain with affecting the lower limbs. 4. Lower back pain should persist for more than six weeks and fail to improve with conservative treat…
Contacts

No contact information available.